A liquid pharmaceutical composition comprising (a) a bispecific antibody construct comprising at least three domains, wherein: • the first domain binds to a target cell surface antigen selected from the group consisting of a tumor antigen, an antigen specific for an immunological disorder or a viral antigen, and has an isoelectric point (pl) in the range of 4 to 9.5; • the second domain binds to a second antigen, which is an extracellular epitope of CD3, the human and/or the Macaca CD3ε chain and has a pl in the range of 8 to 10, preferably 8.5 to 9.5; and • the third domain comprises two polypeptide monomers, each comprising a hinge, a CH2 domain and a CH3 domain, wherein said two polypeptide monomers are fused to each other via a peptide linker, wherein the third domain has a pl in the range of 5.5 to 7.5; (b) at least one buffer agent, wherein the at least one buffer agent is an acid selected from the group consisting of acetate, glutamate, citrate, succinate, tartrate, fumarate, maleate, histidine, phosphate, 2-(N-morpholino) ethanesulfonate or a combination thereof; (c) at least one saccharide, wherein the at least one saccharide is selected from the group consisting of monosaccharide, disaccharide, cyclic polysaccharide, sugar alcohol, linear branched dextran or linear non-branched dextran, wherein the disaccharide is preferably selected from the group consisting of sucrose, trehalose and mannitol, sorbitol, and combinations thereof, or wherein the sugar alcohol is preferably sorbitol; and (d) at least one surfactant, wherein the at least one surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, poloxamer 188, pluronic F68, triton X-100, polyoxyethylen, PEG 3350, PEG 4000 and combinations thereof; and wherein the pH of the pharmaceutical composition is in the range of 4.0 to 5.0. (a) a bispecific antibody construct comprising at least three domains, wherein: • the first domain binds to a target cell surface antigen selected from the group consisting of a tumor antigen, an antigen specific for an immunological disorder or a viral antigen, and has an isoelectric point (pl) in the range of 4 to 9.5; • the second domain binds to a second antigen, which is an extracellular epitope of CD3, the human and/or the Macaca CD3ε chain and has a pl in the range of 8 to 10, preferably 8.5 to 9.5; and • the third domain comprises two polypeptide monomers, each comprising a hinge, a CH2 domain and a CH3 domain, wherein said two polypeptide monomers are fused to each other via a peptide linker, wherein the third domain has a pl in the range of 5.5 to 7.5; • the first domain binds to a target cell surface antigen selected from the group consisting of a tumor antigen, an antigen specific for an immunological disorder or a viral antigen, and has an isoelectric point (pl) in the range of 4 to 9.5; • the second domain binds to a second antigen, which is an extracellular epitope of CD3, the human and/or the Macaca CD3ε chain and has a pl in the range of 8 to 10, preferably 8.5 to 9.5; and • the third domain comprises two polypeptide monomers, each comprising a hinge, a CH2 domain and a CH3 domain, wherein said two polypeptide monomers are fused to each other via a peptide linker, wherein the third domain has a pl in the range of 5.5 to 7.5; (b) at least one buffer agent, wherein the at least one buffer agent is an acid selected from the group consisting of acetate, glutamate, citrate, succinate, tartrate, fumarate, maleate, histidine, phosphate, 2-(N-morpholino) ethanesulfonate or a combination thereof; (c) at least one saccharide, wherein the at least one saccharide is selected from the group consisting of monosaccharide, disaccharide, cyclic polysaccharide, sugar alcohol, linear branched dextran or linear non-branched dextran, wherein the disaccharide is preferably selected from the group consisting of sucrose, trehalose and mannitol, sorbitol, and combinations thereof, or wherein the sugar alcohol is preferably sorbitol; and (d) at least one surfactant, wherein the at least one surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, poloxamer 188, pluronic F68, triton X-100, polyoxyethylen, PEG 3350, PEG 4000 and combinations thereof;